September 09. 2021. Palobiofarma announces the finalization of the Phase IIa clinical trial of it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis

The Phase II trial studies the safety, tolerability and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care (5-ASA). 30 patients were recruited in the trial, 20 of them received PBF-677 (200mg) + 5-ASA(4g) and 10 of them received just the standard of care (4g of 5-ASA) once a day for 28 days. Final results of the clinical trial will be announced soon in an international gastroenterology meeting.

The release as fetched from its publisher. palobiofarma.com ↗